Imagine yourself walking through the streets of a strange city.  You have places to go but, as with every journey, the destination is merely the end result.  You pass many points of interest along the …

One of the most heartbreaking and frustrating diagnoses discussed today is that of SIDS, or sudden infant death syndrome. Although the term has been used for years, it is considered a diagnosis of exclusion, …

In a Wall Street Journal (WSJ) opinion piece, one of the nation’s top economists says more Americans would benefit from the health plan presented by presidential hopeful, John McCain, than that of his opponent, Barack …

The committee of experts advising the US Food and Drug Administration’s (FDA’s) commissioner released a report that says the FDA is wrong about the safety of bisphenol A (BPA), a chemical compound used throughout the …

Presidential campaigns aside, the campaign against smoking has a sure winner.  Every smoker with a desire to quit, said to be 70% of all American smokers, is a winner but most will require medical intervention …

Almost 1.3 million Americans have rheumatoid arthritis (RA), a painful chronic condition that stiffens two or more joints.  Heart failure often accompanies RA although, until recently, no direct link between the two has been established.  …

Researchers at the University of Michigan’s (UM’s) School of Public Health just released the first-year findings of a study of successful non-pharmaceutical methods that might reduce the risk of developing influenza, or the flu.  It …

A 2008 study published in Lancet, a 185-year-old prestigious British medical journal, analyzed the impact of chemotherapy on active symptom control treatment in malignant pleural mesothelioma patients. The authors of the scientific study explained the …

DURHAM, N.C. — Duke University Medical Center scientists have figured out which type of B cells act — and at what time — to keep a multiple-sclerosis (MS)-like disease under control, knowledge that will help …

The US Food and Drug Administration (FDA) has announced labeling changes that affect the popular psoriasis drug, efalizumab, marketed under the brand name, Raptiva. The updated label warning is the result of the increased …